Login / Signup

Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.

Catherine L WetzelThomas Lee SuttonStuart GardinerMaryam FarinolaNathalie JohnsonJennifer R Garreau
Published in: Journal of surgical oncology (2021)
The loss of HER2-positivity following NAT is not associated with worse 5-year RFS or OS. We do not recommend retesting HER2 status following NAT for the purpose of clinical management; these patients should complete targeted adjuvant therapy.
Keyphrases
  • rectal cancer
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • lymph node
  • prostate cancer
  • cancer therapy
  • squamous cell carcinoma
  • patient reported outcomes
  • drug delivery
  • robot assisted